We recently published 10 Stocks Jim Cramer Discussed As He Shared Key Insights From Morgan Stanley’s CEO. Johnson & Johnson is one of the stocks Jim Cramer recently discussed.
Johnson & Johnson’s shares are up by 5% since its latest earnings report, which saw it post $23.7 billion in sales to beat analyst estimates of $22.8 billion. Crucially, the shares were helped by Johnson & Johnson’s midpoint annual revenue guidance, which the firm raised by $2 billion, and by its midpoint full year EPS of $10.85, which marked a 25-cent jump. Cramer was impressed by Johnson & Johnson’s results and shared that the firm surprised on 15 different metrics:
“And then yesterday, unheard and unsung, but we’re going to change that. Johnson & Johnson. Johnson & Johnson delivered a quarter, I counted 15 separate surprises. . .15 different things. That they beat on. All sorts of different metrics.”
A smiling baby with an array of baby care products in the foreground.
Previously, he discussed Johnson & Johnson’s prospects ahead of the earnings release:
“Johnson & Johnson kicks off pharma earnings season on Wednesday, and I think once again, the company will not be rewarded for its consistency or its originality because there’s still the sort of the talc lawsuits hanging over it. I don’t mind JNJ fighting the plaintiff’s part, but it sure puts a damper on the stock.”
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
